SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two upcomin.
Private equity firm KKR teamed up with OMX Ventures to lead the seed investment in Replay, a company developing a suite of technologies that could overcome capacity limitations of adeno-associated viruses used for genetic medicines delivery. Duchenne muscular dystrophy is among the disease targets of the new startup.
Press Release 4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing 7 June 2022 London & Greater Philadelphia - 4BIO Capital
Code Biotherapeutics uses synthetic DNA as the foundation for its genetic medicines, which the startup claims offer several key advantages compared to genetic medicines delivered via engineered viruses. The startup plans to use its new capital to develop lead programs in Duchenne muscular dystrophy and type 1 diabetes.